An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor for heart attacks,
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Hosted on MSN1d
siRNA Agent Slashes Lipoprotein(a) LevelsCHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback